Protalix BioTherapeutics, Inc. (NYSE:PLX) Stock Position Increased by Squarepoint Ops LLC

Squarepoint Ops LLC boosted its position in Protalix BioTherapeutics, Inc. (NYSE:PLX) by 673.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 137,764 shares of the company’s stock after purchasing an additional 119,949 shares during the quarter. Squarepoint Ops LLC owned about 0.19% of Protalix BioTherapeutics worth $161,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new position in shares of Protalix BioTherapeutics in the 2nd quarter worth approximately $37,000. Ground Swell Capital LLC acquired a new position in shares of Protalix BioTherapeutics in the 2nd quarter worth approximately $73,000. Finally, Virtu Financial LLC acquired a new position in shares of Protalix BioTherapeutics in the 1st quarter worth approximately $198,000. 16.53% of the stock is currently owned by institutional investors.

Protalix BioTherapeutics Price Performance

Shares of PLX opened at $1.08 on Monday. The firm’s 50 day moving average is $1.02 and its 200-day moving average is $1.11. The stock has a market capitalization of $79.42 million, a P/E ratio of -5.40 and a beta of 0.70. Protalix BioTherapeutics, Inc. has a 12-month low of $0.82 and a 12-month high of $1.90.

Protalix BioTherapeutics (NYSE:PLX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.05). The business had revenue of $13.47 million during the quarter, compared to analyst estimates of $12.50 million. Protalix BioTherapeutics had a negative return on equity of 45.15% and a negative net margin of 38.62%. During the same period in the prior year, the firm earned ($0.07) EPS. As a group, equities research analysts forecast that Protalix BioTherapeutics, Inc. will post 0.06 EPS for the current fiscal year.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.